OBJECTIVE: To determine how often warfarin was prescribed to patients with nonrheumatic atrial fibrillation in our community in 1992 when randomized trials had demonstrated that warfarin could prevent stroke with little increase in the rate of hemorrhage, and to determine whether warfarin was prescribed less frequently to older patients—the patients at highest risk of stroke but of most concern to physicians in terms of the safety of warfarin.
DESIGN: Cross-sectional study. Appropriateness of warfarin was classified for each patient based on the independent judgments of three physicians applying relevant evidence and guidelines.
SETTING: Two teaching hospitals and five community-based practices.
PATIENTS: Consecutive patients with nonrheumatic atrial fibrillation (n=189).
MEASUREMENTS AND MAIN RESULTS: Warfarin was prescribed to 44 (23%) of the 189 patients. Warfarin was judged appropriate in 98 patients (52%), of whom 36 (37%) were prescribed warfarin. Warfarin was prescribed to 11 (14%) of 76 patients aged 75 years or older with hypertension, diabetes mellitus, or past stroke, the group at highest risk of stroke. In a multivariable logistic regression model controlling for appropriateness of warfarin and other patient characteristics, patients aged 75 years or older were less likely than younger patients to be treated with warfarin (odds ratio 0.25; 95% confidence interval 0.10, 0.65).
CONCLUSIONS: Warfarin was prescribed infrequently to these patients with nonrheumatic atrial fibrillation, especially the older patients and even the patients for whom warfarin was judged appropriate. These findings indicate a substantialopportunity to prevent stroke.
Warfarin atrial fibrillation, nonrheumatic stroke prevention prescription practices physician behavior quality of care
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation; a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561–4.PubMedCrossRefGoogle Scholar
Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469–73.PubMedCrossRefGoogle Scholar
Chang HJ, Bell JR. Deroo DB, Kirk JW, Wasson JH. Dartmouth Primary Care COOP Project. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:81–4.CrossRefGoogle Scholar
Kutner M, Nixon G, Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950–3.PubMedCrossRefGoogle Scholar
Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175–9.PubMedCrossRefGoogle Scholar
Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–11.CrossRefGoogle Scholar
Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of stroke prevention in atrial fibrillation study. N Engl J Med. 1990;322:863–8.Google Scholar
Connolly SJ, Laupacis A, Gent M, Roberts RS, Caims JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349–55.PubMedCrossRefGoogle Scholar
Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–12.PubMedCrossRefGoogle Scholar
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.CrossRefGoogle Scholar
Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1992;102:426S-33S.PubMedGoogle Scholar
Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108:352S-9S.PubMedGoogle Scholar
Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945–53.PubMedCrossRefGoogle Scholar
Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ. 1993;307:1045.PubMedCrossRefGoogle Scholar
Wennberg JE, Mulley AG Jr., Hanley D, et al. An assessment of prostatectomy for benign urinary tract obstruction. Geographic variations and the evaluation of medical care outcomes. JAMA. 1988;259:3027–30.PubMedCrossRefGoogle Scholar
Chassin MR, Brook RH, Park RE, et al. Variations in the use of medical and surgical services by the Medicare population. N Engl J Med. 1986;314:285–90.PubMedCrossRefGoogle Scholar
Anderson FA Jr., Wheeler B, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Intern Med. 1994;154:669–77.PubMedCrossRefGoogle Scholar
Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hanna WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306–11.PubMedCrossRefGoogle Scholar
Lomas J, Enkin M, Anderson GM, Hannah WJ, Vayda E, Singer J. Opinion leaders versus audit and feedback to implement practice guidelines: delivery after previous cesarean section. JAMA. 1991;265:2202–7.PubMedCrossRefGoogle Scholar
Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med. 1993;118:511–20.PubMedGoogle Scholar
Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970–9.PubMedGoogle Scholar
Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144–52.PubMedGoogle Scholar
Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989;87:153–9.PubMedCrossRefGoogle Scholar
Stroke Prevention in Atrial Fibrillation Study Group Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet. 1994;343:687–91.Google Scholar
Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241–7.PubMedCrossRefGoogle Scholar
CAST Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12.CrossRefGoogle Scholar
Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health study). Am J Cardiol. 1994;74:236–41.PubMedCrossRefGoogle Scholar
Flegel KM. Hutchinson TA, Groome PA, Tousignant P. Factors relevant to preventing embolic stroke in patients with non-rheumatic atrial fibrillation. J Clin Epidemiol. 1991;44:551–60.PubMedCrossRefGoogle Scholar